search
Back to results

Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions (SS-SBVPT)

Primary Purpose

Premature Ventricular Contraction

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Shensong Yangxin capsule
placebo Capsule
Sponsored by
kejiang Cao
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premature Ventricular Contraction focused on measuring sinus bradycardia, ventricular premature contraction

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 Years to 70 Years old
  • Documented sinus bradycardia with average heart rate at 45-59 by 24hours ambulatory EKG
  • Ventricular premature beats: >1000 beats/24 hours

Exclusion Criteria:

  • Younger than 18 years or older than 75 years
  • Symptomatic sinus arrest >3 seconds or high degree atrioventricular block indicated for pacemaker
  • Subject suffered from acute coronary syndrome in last three months (Acute myocardial infarction of ST segment elevation and non ST segment elevation, unstable angina
  • To be complicated with persistent atrial fibrillation, or paroxysmal atrial fibrillation >5% during 24hrs ambulatory EKG or acute myocarditis
  • To be complicated with ventricular fibrillation, torsion type ventricular heartbeat rate, sustained ventricular tachycardia, or non sustained ventricular tachycardia with rapid ventricular rate and hemodynamic disorders
  • Sinus heart rate less than 45 beats/minutes and needs to receive the pacemaker or has received pacemaker, or with ICD,CRTP/D

Sites / Locations

  • the First Affiliated Hospital of Nanjing Medical Universtiy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Shensong Yangxin capsule

placebo Capsule

Arm Description

Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks

placebo Capsule 4 granules t.i.d. by mouth for 8 weeks

Outcomes

Primary Outcome Measures

numbers of the Premature ventricular contractions detected by 24 houres ambulatory EKG
average heart rate detected by 24-hour ambulatory ECG

Secondary Outcome Measures

numbers of the Premature ventricular contractions detected by 24-hour ambulatory ECG
average heart rate detected by 24-hour ambulatory ECG

Full Information

First Posted
December 6, 2012
Last Updated
December 13, 2012
Sponsor
kejiang Cao
Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital, Third Military Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT01750775
Brief Title
Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions
Acronym
SS-SBVPT
Official Title
Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions Multi-center,Randomized, Double-blind, Placebo-controlled Clinical Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2012
Overall Recruitment Status
Unknown status
Study Start Date
August 2012 (undefined)
Primary Completion Date
September 2013 (Anticipated)
Study Completion Date
December 2013 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
kejiang Cao
Collaborators
Chinese Academy of Medical Sciences, Fuwai Hospital, Third Military Medical University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the effects of Chinese medicine Shansong Yangxin capsule for sinus bradycardia complicated with ventricular premature beats.
Detailed Description
Premature ventricular contractions is one of the most common symptomatic arrhythmia. Antiarrhythmia drugs for premature ventricular contractions, such as beta-blockers and sodium channel blockers, can cause bradycardia. For sinus bradycardia patients complicated with premature ventricular contractions, it's hard for doctors to make decision. The purpose of the study is to assess the effects of Chinese medicine Shansong Yangxin capsule for sinus bradycardia complicated with ventricular premature beats, which based on the numbers of premature ventricular contractions and average hear rate in 24-hour ambulatory electrocardiogram (ECG) after 8 weeks treatment as the primary endpoint of the study. Secondary endpoints are evaluation of the Shensong Yangxin capsule on quality of life. This study is a randomized, double-blind, placebo controlled, multi-center trial. Sinus bradycardia patients(average heart rate 45-59 beat per minute) associated with premature ventricular contractions (PVC number >10000 / 24h), are involved in the study. Patients are randomly assigned into Shensong Yangxin capsule group or placebo group, with the capsule administration of 4 granules t.i.d.for 8 weeks. 24-hour ambulatory ECG, are observed at baseline,4 weeks and 8 weeks after the intervention. The primary outcomes are the numbers of premature ventricular contractions and average heat rate in 24-hour ambulatory ECG, and the secondary outcomes is Minnesota living with heart failure questionnaire (MLHFQ).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Ventricular Contraction
Keywords
sinus bradycardia, ventricular premature contraction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
330 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Shensong Yangxin capsule
Arm Type
Experimental
Arm Description
Shensong Yangxin capsule 4 granules t.i.d. by mouth for 8weeks
Arm Title
placebo Capsule
Arm Type
Placebo Comparator
Arm Description
placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Intervention Type
Drug
Intervention Name(s)
Shensong Yangxin capsule
Intervention Description
ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
Intervention Type
Drug
Intervention Name(s)
placebo Capsule
Intervention Description
placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
Primary Outcome Measure Information:
Title
numbers of the Premature ventricular contractions detected by 24 houres ambulatory EKG
Time Frame
8 weeks
Title
average heart rate detected by 24-hour ambulatory ECG
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
numbers of the Premature ventricular contractions detected by 24-hour ambulatory ECG
Time Frame
4 weeks
Title
average heart rate detected by 24-hour ambulatory ECG
Time Frame
4 weeks
Other Pre-specified Outcome Measures:
Title
Minnesota living with heart failure questionnaire (MLHFQ)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 Years to 70 Years old Documented sinus bradycardia with average heart rate at 45-59 by 24hours ambulatory EKG Ventricular premature beats: >1000 beats/24 hours Exclusion Criteria: Younger than 18 years or older than 75 years Symptomatic sinus arrest >3 seconds or high degree atrioventricular block indicated for pacemaker Subject suffered from acute coronary syndrome in last three months (Acute myocardial infarction of ST segment elevation and non ST segment elevation, unstable angina To be complicated with persistent atrial fibrillation, or paroxysmal atrial fibrillation >5% during 24hrs ambulatory EKG or acute myocarditis To be complicated with ventricular fibrillation, torsion type ventricular heartbeat rate, sustained ventricular tachycardia, or non sustained ventricular tachycardia with rapid ventricular rate and hemodynamic disorders Sinus heart rate less than 45 beats/minutes and needs to receive the pacemaker or has received pacemaker, or with ICD,CRTP/D
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kejiang Cao, M.D
Organizational Affiliation
The First Affiliated Hospital with Nanjing Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
the First Affiliated Hospital of Nanjing Medical Universtiy
City
Nanjing
State/Province
Jiangsu
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
30949218
Citation
Zhang F, Zou J, Yu H, Li X, Kojodjojo P, Cai X, Zhang S, Huang C, Hong K, Yu B, Li G, Luo S, Zhou S, Zheng Y, Fan J, Cao X, Tao G, Sheng G, Bai Z, Jiang S, Liu X, Gu W, Chen F, Cao K. Acute Efficacy of a Traditional Chinese Medicine for Treatment of Frequent Premature Ventricular Contractions in Patients with Concomitant Sinus Bradycardia: Results from a Double-Blind, Placebo-Controlled, Multicentre, Randomized Clinical Trial. Evid Based Complement Alternat Med. 2019 Mar 4;2019:3917282. doi: 10.1155/2019/3917282. eCollection 2019.
Results Reference
derived

Learn more about this trial

Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions

We'll reach out to this number within 24 hrs